Information Provided By:
Fly News Breaks for April 12, 2017
VSTM
Apr 12, 2017 | 17:12 EDT
Oppenheimer analyst Leah Rush Cann initiated Verastem with an Outperform and a $6 price target, anticipating the company will commercialize its development-stage leukemia drug Duvelisib in 2019.
News For VSTM From the Last 2 Days
There are no results for your query VSTM